A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
Status:
Completed
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
RUC-4 is a novel, promising and fast acting (5-15 minutes) αIIbβ3 receptor antagonist with a
high-grade inhibition of platelet aggregation (≥80%) shortly after subcutaneous
administration. This study is designed to extend the findings in CEL-01 to patients with
ST-elevation myocardial Infarction (STEMI) presenting to the cardiac catheterization
laboratory with planned coronary angioplasty.
Phase:
Phase 2
Details
Lead Sponsor:
CeleCor Therapeutics
Collaborators:
Diagram B.V. Diagram BV ST. Antonius hospital Nieuwegein Syneos Health